

**In the Claims:**

Please enter the following rewritten claims as follows:

E 1.  
1. (currently amended) An antisense oligonucleotide, or analog thereof, from about 7 15 to about 100 nucleotides in length comprising at least 15 consecutive nucleotides from a sequence complementary to ~~a transcribed region of~~ a human ~~or rodent~~ neuropilin gene mRNA, wherein said mRNA has a sequence as set forth in SEQ ID NO:33 and wherein said oligonucleotide, or analog thereof, specifically binds to a nucleic acid comprising a sequence corresponding to said ~~transcribed region~~ mRNA and inhibits neuropilin expression in a human ~~or rodent~~.

2. (previously amended) The antisense oligonucleotide, or analog thereof, of Claim 1 further comprising one or more phosphorothioate internucleotide linkages.

3. (currently amended) The antisense oligonucleotide, or analog thereof, of Claim 1 further comprising additional nucleotides not complementary to ~~the transcribed region of~~ the neuropilin ~~gene~~ mRNA.

4. (currently amended) A vector comprising an oligonucleotide sequence from about 7 to about 100 nucleotides in length comprising a sequence complementary to a ~~transcribed region of a human or rodent neuropilin gene~~ mRNA, wherein said mRNA has a sequence as set forth in SEQ ID NO:33 and wherein said oligonucleotide, or analog thereof, specifically binds to a nucleic acid comprising a sequence corresponding to said ~~transcribed region~~ mRNA and inhibits neuropilin expression in a human ~~or rodent~~.

E' 5. (currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and an effective amount of an antisense oligonucleotide, or analog thereof, from about 7 15 to about 100 nucleotides in length comprising at least 15 consecutive nucleotides from a sequence complementary to ~~a transcribed region of a human or rodent neuropilin gene~~ mRNA, wherein said mRNA has a sequence as set forth in SEQ ID NO:33 and wherein said oligonucleotide, or analog thereof, specifically binds to a nucleic acid comprising a sequence corresponding to said ~~transcribed region~~ mRNA and inhibits neuropilin expression in a human ~~or rodent~~.

6. (currently amended) A method for inhibiting the growth of a human ~~or rodent~~ tumor comprising, administering to a human ~~or rodent~~ suspected of having the tumor an effective amount of an antisense oligonucleotide, or analog thereof, from about 20 to about 100 nucleotides in length comprising a sequence complementary to ~~a transcribed region of~~ a human ~~or rodent~~ neuropilin ~~gene~~ mRNA under conditions such that the growth of the tumor is inhibited, wherein said mRNA has a sequence as set forth in SEQ ID NO:33 and wherein said oligonucleotide, or analog thereof, specifically binds to a nucleic acid comprising a sequence corresponding to said ~~transcribed region~~ mRNA.

7. (currently amended) The method according to Claim 6 further comprising the step of administering to the human ~~or rodent~~ a chemotherapeutic agent.

8. (original) The method according to Claim 6 wherein the oligonucleotide is from 20 to about 100 nucleotides in length and comprises a sequence selected from the group consisting of SEQ ID NOs:1 – 30.

9. (original) The method according to Claim 6 wherein the oligonucleotide is nuclease resistant.

10. (currently amended) A method for inhibiting the metastasis of a human ~~or rodent~~ tumor comprising, administering to a human ~~or rodent~~ suspected of having a metastatic tumor an effective amount of an antisense oligonucleotide, or analog thereof, from about 20 nucleotides to about 100 nucleotides in length comprising a sequence complementary to a ~~transcribed region of~~ a human ~~or rodent~~ neuropilin ~~gene~~ mRNA under conditions such that the metastasis of the tumor is inhibited, wherein said mRNA has a sequence as set forth in SEQ ID NO:33 and wherein said oligonucleotide, or analog thereof, specifically binds to a nucleic acid comprising a sequence corresponding to said ~~transcribed region~~ mRNA.

11. (currently amended) The method according to Claim 10 further comprising the step of administering to the human ~~or rodent~~ a chemotherapeutic agent.

12. (original) The method according to Claim 10 wherein the oligonucleotide is nuclease resistant.

13. (original) The method according to Claim 10 wherein the oligonucleotide is from 20 to about 100 nucleotides in length and comprises a sequence selected from the group consisting of SEQ ID NOs:1 – 30.

14. (currently amended) A method for inhibiting neovascularization comprising, administering to a human ~~or rodent~~ an effective amount of an antisense oligonucleotide, or analog thereof, from about 20 nucleotides to about 100 nucleotides in length comprising a sequence complementary to ~~a transcribed region of a human or rodent neuropilin gene~~ mRNA under conditions such that neovascularization is inhibited, wherein said mRNA has a sequence as set forth in SEQ ID NO:33 and wherein said oligonucleotide, or analog thereof, specifically binds to a nucleic acid comprising a sequence corresponding to ~~said transcribed region~~ mRNA.

15. (original) The method according to Claim 14 wherein the oligonucleotide is nuclease resistant.

16. (original) The method according to Claim 14 wherein the oligonucleotide is from 20 to about 100 nucleotides in length and comprises a sequence selected from the group consisting of SEQ ID NOs:1 – 30.

17. (original) The antisense oligonucleotide, or analog thereof, according to claim 1, wherein the oligonucleotide is from 20 to about 100 nucleotides in length and comprises a sequence selected from the group consisting of SEQ ID NOs:1 – 30.

18. (original) The vector according to claim 4, wherein the oligonucleotide sequence is from 20 to about 100 nucleotides in length and comprises a sequence selected from the group consisting of SEQ ID NOs:1 – 30.

19. (original) The pharmaceutical composition according to claim 5, wherein the oligonucleotide is from 20 to about 100 nucleotides in length and comprises a sequence selected from the group consisting of SEQ ID NOs:1 – 30.

20. (withdraw)

21. (withdraw)

22. (withdraw)

23. (currently amended) A method of inhibiting the growth of cancer cells comprising, contacting said cancer cells *in vitro* with an effective amount of an antisense oligonucleotide, or analog thereof, from about 7 to about 100 nucleotides in length comprising a sequence complementary to ~~a transcribed region of a human or rodent neuropilin gene~~ mRNA under conditions such that the growth of the cancer cells is inhibited, wherein said mRNA has a sequence as set forth in SEQ ID NO:33.

24. (previously added) The method according to claim 23, wherein the oligonucleotide is from 20 to about 100 nucleotides in length and comprises a sequence selected from the group consisting of SEQ ID NOs:1 – 30.

In re Application of  
Wright et al.  
Application No. 09/296,264  
Filed: April 22, 1999  
Page 8

PATENT  
Attorney Docket No.: MBM1250-2

25. (previously added) The method according to Claim 23 wherein the  
oligonucleotide is nuclease resistant.

26. (withdraw)

27. (withdraw)

28. (withdraw)

29. (withdraw)

30. (currently amended) The method according to Claim ~~28 or 29~~ 6 or 10,  
comprising administering said antisense oligonucleotide, or analog thereof, by infusion.

---